Well, statistically speaking there should have been at-least equal number of vaccine vs placebo subjects with a total size of more than 80 but, it does not matter as this study was never meant to find the true statistical difference.
As said in the Webinar, The study was for safety and efficacy (i.e. immune response).
Even if it's statistically significant, the 'power of the study' would be very low.
Power of the study means the ability to find a true difference when there is actually a difference.
This is when the phase 3 trial comes in play to find the true difference with big sample size and significant 'power of study'. (Bigger the sample size, better the power.)
IMHO, the results of this study are good enough to go ahead and plan the IIb trial.
The HSV space has great unmet need and there is no cure. I totally understand the HSV vaccine is not gonna cure the disease but it would be a functional cure where by the breakouts are reduced and there is no need for taking daily pills for suppression.
No matter whats the ultimate phase III results this vaccine is going to have its place in the treatment and may be in prevention of HSV , also in reducing the transmissions.
Financially, yes the funding should be from collaboration or private players or something else. I am sure the management will figure this out.
Prof Frazer has great track record and in near future this vaccine and / or Genocea is going to be the nearest possible option for cure of genital herpes.
- Forums
- ASX - By Stock
- AVR
- Ann: Admedus Releases Results of HSV-2 Phase IIa Study
Ann: Admedus Releases Results of HSV-2 Phase IIa Study, page-177
-
- There are more pages in this discussion • 174 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$12.19 |
Change
0.000(0.00%) |
Mkt cap ! $257.6M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | $11.68 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$12.20 | 1789 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 11.680 |
2 | 520 | 11.600 |
1 | 1000 | 11.500 |
1 | 80 | 11.250 |
1 | 1000 | 11.200 |
Price($) | Vol. | No. |
---|---|---|
12.200 | 1789 | 1 |
12.500 | 500 | 1 |
12.850 | 99 | 1 |
13.300 | 200 | 1 |
13.500 | 200 | 1 |
Last trade - 07.00am 02/10/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
Day chart unavailable
The Watchlist
TON
TRITON MINERALS LTD
Adrian Costello, Executive Director
Adrian Costello
Executive Director
Previous Video
Next Video
SPONSORED BY The Market Online